Short answer
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026.
BIOCRYST PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026, announced August 5, 2026
- Press release covers financial results and recent corporate developments
- Conference call and webcast scheduled to discuss Q2 performance
- Detailed figures and management commentary in Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Exhibit 99.1 contains the substantive Regulation FD disclosure relevant to investors
- Item 7.01 signals public distribution of material company information outside periodic reports
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $218.3M, up 34% YoY, with ORLADEYO revenue $158.2M, up 1% YoY
- Operating profit $98.5M and non-GAAP operating profit $113.2M, supported by licensing revenue
- FY2026 total revenue guidance raised to $690M-$715M from $635M-$660M, while ORLADEYO guidance remained $625M-$645M
- Navenibart licensing deal generated $55.7M Q2 revenue, with $275M potential milestones and 18%-30% royalties
- Pediatric ORLADEYO shipments began August 3, while ALPHA-ORBIT enrollment completion targets Q3 2027 results
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BIOCRYST PHARMACEUTICALS INC 8-K filings
Get the next BCRX 8-K as it lands
Follow BCRX for push alerts, or ask the research agent what this filing means.